An overview of NIAID-supported efforts to evaluate potential new therapies for Respiratory Syncytial Virus (RSV).

Information about preventive medicine for respiratory syncytial virus (RSV) and NIAID-supported research.

An overview of NIAID research developments about Yersinia pestis biology and genetics.

Antiviral drugs for treating the flu are oseltamivir (Tamiflu®), zanamivir (Relenza®), and peramivir (Rapivab®). These drugs interrupt the function of neuraminidase on the virus surface and prevent the release of viral particles from infected host cells. However, antimicrobial resistance is an ongoing challenge.

Flu can be difficult to diagnose, because its most visible symptoms of fever, cough, and aches are similar to other common illnesses. Researchers have developed rapid diagnostic tests that distinguishing flu type A and flu type B such as paper-strip test, Lab-in-a-Tube, FilmArray, Xpert Flu A/B, and QuickVue.

Locations of Vaccine & Treatment Evaluation Unit Sites

Helping discover and develop new tuberculosis (TB) drugs is a top NIAID priority.

NIAID supports the development of new and improved diagnostic tools for faster and more accurate diagnosis of early tuberculosis (TB) disease.

An overview of NIAID’s commitment to the global research community’s focus on finding new ways to prevent tuberculosis (TB) disease in children and adults.